Chiome Bioscience Inc. (TYO:4583)
76.00
+1.00 (1.33%)
Nov 18, 2026, 10:20 AM JST
Chiome Bioscience Revenue
Chiome Bioscience had revenue of 133.32M JPY in the quarter ending September 30, 2026, with 12.96% growth. This brings the company's total for the last twelve months to 630.45M, down -13.40% year-over-year. In the year 2025, Chiome Bioscience had annual revenue of 593.29M, down -24.02%. That makes Chiome Bioscience the 40,801st largest company in the world by revenue and 3,830th in Japan.
Revenue (ttm)
630.45M
Revenue Growth
-13.40%
P/S Ratio
9.62
Revenue / Employee
11.61M
Employees
53
Market Cap
6.00B
Revenue by Segment
- Drug Discovery Support Business 577.86M 74.0%
- Drug Discovery Business 202.95M 26.0%
Fiscal year ended Dec 31, 2024 See the full Chiome Bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 593.29M | -187.52M | -24.02% |
| Dec 31, 2024 | 780.81M | 98.35M | 14.41% |
| Dec 31, 2023 | 682.46M | 51.65M | 8.19% |
| Dec 31, 2022 | 630.82M | -82.12M | -11.52% |
| Dec 31, 2021 | 712.93M | 232.08M | 48.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Soiken Holdings | 3.87B |
| CellSource | 3.67B |
| StemCell Institute | 2.81B |
| OncoTherapy Science | 712.00M |
| Cyfuse Biomedical K.K. | 305.00M |
| Nano Holdings | 202.00M |
| CellSeed | 161.00M |
| ADR Biomedical Holdings | 101.00M |